MCI
REGN icon

McDonald Capital Investors’s Regeneron Pharmaceuticals REGN Stock Holding History

McDonald Capital Investors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$120M Sell
193,038
-12,833
-6% -$8.74M 8.79% 3
2026
Q1 		$159M Sell
205,871
-2,370
-1% -$1.81M 10.89% 2
2025
Q4 		$161M Sell
208,241
-5,090
-2% -$3.46M 9.86% 2
2025
Q3 		$120M Sell
213,331
-4,714
-2% -$2.67M 7.46% 5
2025
Q2 		$114M Buy
218,045
+21,272
+11% +$11.9M 7.18% 7
2025
Q1 		$125M Buy
196,773
+26,593
+16% +$18.3M 7.87% 4
2024
Q4 		$121M Buy
170,180
+33,727
+25% +$28.3M 7.61% 6
2024
Q3 		$143M Sell
136,453
-2,746
-2% -$3.06M 8.8% 4
2024
Q2 		$146M Sell
139,199
-1,814
-1% -$1.76M 9.14% 3
2024
Q1 		$136M Sell
141,013
-2,516
-2% -$2.39M 8.5% 3
2023
Q4 		$126M Sell
143,529
-2,590
-2% -$2.13M 8.79% 3
2023
Q3 		$120M Sell
146,119
-3,080
-2% -$2.42M 9.38% 3
2023
Q2 		$107M Sell
149,199
-3,265
-2% -$2.52M 8% 4
2023
Q1 		$125M Sell
152,464
-4,122
-3% -$3.11M 9.55% 2
2022
Q4 		$113M Sell
156,586
-4,385
-3% -$3.24M 9.39% 4
2022
Q3 		$111M Sell
160,971
-3,111
-2% -$1.96M 9.85% 3
2022
Q2 		$97M Sell
164,082
-1,531
-0.9% -$995K 8.1% 4
2022
Q1 		$116M Sell
165,613
-540
-0.3% -$342K 8.25% 4
2021
Q4 		$105M Sell
166,153
-1,675
-1% -$1.03M 7.36% 5
2021
Q3 		$102M Sell
167,828
-6,610
-4% -$4.1M 7.87% 4
2021
Q2 		$97.4M Sell
174,438
-3,368
-2% -$1.71M 7.32% 5
2021
Q1 		$84.1M Sell
177,806
-365
-0.2% -$178K 6.71% 9
2020
Q4 		$86.1M Sell
178,171
-1,768
-1% -$954K 7.16% 7
2020
Q3 		$101M Sell
179,939
-1,359
-0.7% -$824K 8.98% 3
2020
Q2 		$113M Sell
181,298
-10,270
-5% -$5.83M 10.61% 2
2020
Q1 		$93.5M Sell
191,568
-4,295
-2% -$1.77M 9.1% 4
2019
Q4 		$73.5M Sell
195,863
-13,817
-7% -$4.65M 6.26% 11
2019
Q3 		$58.2M Buy
209,680
+16,680
+9% +$4.94M 4.92% 11
2019
Q2 		$60.4M Buy
193,000
+58,015
+43% +$19.3M 4.92% 11
2019
Q1 		$55.4M Sell
134,985
-5,435
-4% -$2.24M 4.6% 11
2018
Q4 		$52.4M Buy
140,420
+35,885
+34% +$13.1M 4.91% 11
2018
Q3 		$42.2M Buy
104,535
+94,035
+896% +$35.8M 3.5% 11
2018
Q2 		$3.62M Buy
+10,500
New +$3.28M 0.29% 15

Other funds holding REGN

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

McDonald Capital Investors's REGN Position: Q2 2026 in Review

McDonald Capital Investors reduced its Regeneron Pharmaceuticals (REGN) stake by 6.2% in Q2 2026, selling an estimated $8.74M and leaving 193,038 shares worth $120M. The position accounts for 8.79% of the portfolio, ranked #3.

McDonald Capital Investors first reported a position in REGN in Q2 2018 and has held it in 33 quarters since. The position peaked at $161M in Q4 2025. 533 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • McDonald Capital Investors held 193,038 shares of Regeneron Pharmaceuticals worth $120M as of Q2 2026.
  • McDonald Capital Investors sold 12,833 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $8.74M.
  • Regeneron Pharmaceuticals made up 8.79% of McDonald Capital Investors's portfolio in Q2 2026, its #3 holding.
  • McDonald Capital Investors first reported a position in Regeneron Pharmaceuticals in Q2 2018 and has held it in 33 quarters since.
  • McDonald Capital Investors's Regeneron Pharmaceuticals position peaked at $161M in Q4 2025.
  • 533 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on McDonald Capital Investors's 13F filing for Q2 2026, filed 29 Jul 2026.